-
1
-
-
42649145828
-
Epidemiologic and socioeconomic burden of metastatic renal cell carcinoma (mRCC): A literature review
-
K. Gupta, J.D. Miller, J.Z. Li, M.W. Russell, and C. Charbonneau Epidemiologic and socioeconomic burden of metastatic renal cell carcinoma (mRCC): a literature review Cancer Treat Rev 34 2008 193 205
-
(2008)
Cancer Treat Rev
, vol.34
, pp. 193-205
-
-
Gupta, K.1
Miller, J.D.2
Li, J.Z.3
Russell, M.W.4
Charbonneau, C.5
-
2
-
-
67650874081
-
Cancer statistics, 2009
-
A. Jemal, R. Siegel, E. Ward, Y. Hao, J. Xu, and M.J. Thun Cancer statistics, 2009 CA Cancer J Clin 59 2009 225 249
-
(2009)
CA Cancer J Clin
, vol.59
, pp. 225-249
-
-
Jemal, A.1
Siegel, R.2
Ward, E.3
Hao, Y.4
Xu, J.5
Thun, M.J.6
-
3
-
-
33847638137
-
Estimates of the cancer incidence and mortality in Europe in 2006
-
J. Ferlay, P. Autier, M. Boniol, M. Heanue, M. Colombet, and P. Boyle Estimates of the cancer incidence and mortality in Europe in 2006 Ann Oncol 18 2007 581 592
-
(2007)
Ann Oncol
, vol.18
, pp. 581-592
-
-
Ferlay, J.1
Autier, P.2
Boniol, M.3
Heanue, M.4
Colombet, M.5
Boyle, P.6
-
4
-
-
77249178172
-
A survey of therapy for advanced renal cell carcinoma
-
M. Basso, A. Cassano, and C. Barone A survey of therapy for advanced renal cell carcinoma Urol Oncol 28 2009 121 133
-
(2009)
Urol Oncol
, vol.28
, pp. 121-133
-
-
Basso, M.1
Cassano, A.2
Barone, C.3
-
5
-
-
1442290393
-
Prognostic factors for survival in previously treated patients with metastatic renal cell carcinoma
-
R.J. Motzer, J. Bacik, and L.H. Schwartz Prognostic factors for survival in previously treated patients with metastatic renal cell carcinoma J Clin Oncol 22 2004 454 463
-
(2004)
J Clin Oncol
, vol.22
, pp. 454-463
-
-
Motzer, R.J.1
Bacik, J.2
Schwartz, L.H.3
-
6
-
-
27144517504
-
-
Kidney cancer. v.2 National Comprehensive Cancer Network Web site AccessedFebruary2010
-
NCCN clinical practice guidelines in oncology. Kidney cancer. v.2, 2010. National Comprehensive Cancer Network Web site. http://www.nccn.org/ professionals/physician-gls/PDF/kidney.pdf. Accessed February 2010.
-
(2010)
NCCN Clinical Practice Guidelines in Oncology
-
-
-
8
-
-
33846181370
-
Sunitinib versus interferon alfa in metastatic renal-cell carcinoma
-
R.J. Motzer, T.E. Hutson, and P. Tomczak Sunitinib versus interferon alfa in metastatic renal-cell carcinoma N Engl J Med 356 2007 115 124
-
(2007)
N Engl J Med
, vol.356
, pp. 115-124
-
-
Motzer, R.J.1
Hutson, T.E.2
Tomczak, P.3
-
9
-
-
33846148701
-
Sorafenib in advanced clear-cell renal-cell carcinoma
-
B. Escudier, T. Eisen, and W.M. Stadler Sorafenib in advanced clear-cell renal-cell carcinoma N Engl J Med 356 2007 125 134
-
(2007)
N Engl J Med
, vol.356
, pp. 125-134
-
-
Escudier, B.1
Eisen, T.2
Stadler, W.M.3
-
10
-
-
77949890945
-
Pazopanib in locally advanced or metastatic renal cell carcinoma: Results of a randomized phase III trial
-
C.N. Sternberg, I.D. Davis, and J. Mardiak Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial J Clin Oncol 28 2010 1061 1068
-
(2010)
J Clin Oncol
, vol.28
, pp. 1061-1068
-
-
Sternberg, C.N.1
Davis, I.D.2
Mardiak, J.3
-
11
-
-
37349080670
-
Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: A randomised, double-blind phase III trial
-
B. Escudier, A. Pluzanska, and P. Koralewski Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial Lancet 370 2007 2103 2111
-
(2007)
Lancet
, vol.370
, pp. 2103-2111
-
-
Escudier, B.1
Pluzanska, A.2
Koralewski, P.3
-
12
-
-
56749161699
-
Bevacizumab plus interferon alfa compared with interferon alfa monotherapy in patients with metastatic renal cell carcinoma: CALGB 90206
-
B.I. Rini, S. Halabi, and J.E. Rosenberg Bevacizumab plus interferon alfa compared with interferon alfa monotherapy in patients with metastatic renal cell carcinoma: CALGB 90206 J Clin Oncol 26 2008 5422 5428
-
(2008)
J Clin Oncol
, vol.26
, pp. 5422-5428
-
-
Rini, B.I.1
Halabi, S.2
Rosenberg, J.E.3
-
13
-
-
48649107474
-
Efficacy of everolimus in advanced renal cell carcinoma: A double-blind, randomised, placebo-controlled phase III trial
-
R.J. Motzer, B. Escudier, and S. Oudard Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial Lancet 372 2008 449 456
-
(2008)
Lancet
, vol.372
, pp. 449-456
-
-
Motzer, R.J.1
Escudier, B.2
Oudard, S.3
-
14
-
-
34249779568
-
Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma
-
DOI 10.1056/NEJMoa066838
-
G. Hudes, M. Carducci, and P. Tomczak Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma N Engl J Med 356 2007 2271 2281 (Pubitemid 46849157)
-
(2007)
New England Journal of Medicine
, vol.356
, Issue.22
, pp. 2271-2281
-
-
Hudes, G.1
Carducci, M.2
Tomczak, P.3
Dutcher, J.4
Figlin, R.5
Kapoor, A.6
Staroslawska, E.7
Sosman, J.8
McDermott, D.9
Bodrogi, I.10
Kovacevic, Z.11
Lesovoy, V.12
Schmidt-Wolf, I.G.H.13
Barbarash, O.14
Gokmen, E.15
O'Toole, T.16
Lustgarten, S.17
Moore, L.18
Motzer, R.J.19
-
15
-
-
0035818877
-
Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer
-
R.C. Flanigan, S.E. Salmon, and B.A. Blumenstein Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer N Engl J Med 345 2001 1655 1659
-
(2001)
N Engl J Med
, vol.345
, pp. 1655-1659
-
-
Flanigan, R.C.1
Salmon, S.E.2
Blumenstein, B.A.3
-
16
-
-
0035934596
-
Radical nephrectomy plus interferon-alfa-based immunotherapy compared with interferon alfa alone in metastatic renal-cell carcinoma: A randomised trial
-
G.H. Mickisch, A. Garin, H. van Poppel, L. de Prijck, and R. Sylvester Radical nephrectomy plus interferon-alfa-based immunotherapy compared with interferon alfa alone in metastatic renal-cell carcinoma: a randomised trial Lancet 358 2001 966 970
-
(2001)
Lancet
, vol.358
, pp. 966-970
-
-
Mickisch, G.H.1
Garin, A.2
Van Poppel, H.3
De Prijck, L.4
Sylvester, R.5
-
17
-
-
1542327748
-
Cytoreductive nephrectomy in patients with metastatic renal cancer: A combined analysis
-
R.C. Flanigan, G. Mickisch, R. Sylvester, C. Tangen, H. Van Poppel, and E*D. Crawford Cytoreductive nephrectomy in patients with metastatic renal cancer: a combined analysis J Urol 171 2004 1071 1076
-
(2004)
J Urol
, vol.171
, pp. 1071-1076
-
-
Flanigan, R.C.1
Mickisch, G.2
Sylvester, R.3
Tangen, C.4
Van Poppel, H.5
Crawford, E.D.6
-
18
-
-
77949451507
-
Cytoreductive nephrectomy for metastatic RCC in the era of targeted therapy
-
E.J. Abel, and C.G. Wood Cytoreductive nephrectomy for metastatic RCC in the era of targeted therapy Nat Rev Urol 6 2009 375 383
-
(2009)
Nat Rev Urol
, vol.6
, pp. 375-383
-
-
Abel, E.J.1
Wood, C.G.2
-
19
-
-
0034845956
-
Histopathologic analysis of angiogenic factors in localized renal cell carcinoma: The influence of neoadjuvant treatment
-
N. Kawata, H. Yagasaki, and H. Yuge Histopathologic analysis of angiogenic factors in localized renal cell carcinoma: the influence of neoadjuvant treatment Int J Urol 8 2001 275 281
-
(2001)
Int J Urol
, vol.8
, pp. 275-281
-
-
Kawata, N.1
Yagasaki, H.2
Yuge, H.3
-
20
-
-
0035131552
-
Expression levels of genes that regulate metastasis and angiogenesis correlate with advanced pathological stage of renal cell carcinoma
-
J.W. Slaton, K. Inoue, and P. Perrotte Expression levels of genes that regulate metastasis and angiogenesis correlate with advanced pathological stage of renal cell carcinoma Am J Pathol 158 2001 735 743
-
(2001)
Am J Pathol
, vol.158
, pp. 735-743
-
-
Slaton, J.W.1
Inoue, K.2
Perrotte, P.3
-
21
-
-
78049466218
-
-
Clinical trial to assess the importance of nephrectomy (CARMENA). US National Institutes of Health Web site AccessedJuly28,2010
-
Clinical trial to assess the importance of nephrectomy (CARMENA). US National Institutes of Health Web site. http://clinicaltrials.gov/ct2/show/ NCT00930033. Accessed July 28, 2010.
-
-
-
-
22
-
-
34548310217
-
Sunitinib versus interferon-alfa (IFN-α) as first-line treatment of metastatic renal cell carcinoma (mRCC): Updated results and analysis of prognostic factors
-
R.J. Motzer, R.A. Figlin, and T.E. Hutson Sunitinib versus interferon-alfa (IFN-α) as first-line treatment of metastatic renal cell carcinoma (mRCC): Updated results and analysis of prognostic factors J Clin Oncol 25 2007 5024
-
(2007)
J Clin Oncol
, vol.25
, pp. 5024
-
-
Motzer, R.J.1
Figlin, R.A.2
Hutson, T.E.3
-
23
-
-
78049486075
-
The impact of cytoreductive nephrectomy in patients with metastatic renal cell carcinoma (mRCC) treated with vascular endothelial growth factor (VEGF)-targeted therapy
-
March 5-7 San Francisco, CA, USA
-
Choueiri TK, Xie W, Kollmannsberger CK, et al. The impact of cytoreductive nephrectomy in patients with metastatic renal cell carcinoma (mRCC) treated with vascular endothelial growth factor (VEGF)-targeted therapy. Paper presented at: 2010 Genitourinary Cancers Symposium; March 5-7, 2010; San Francisco, CA, USA.
-
(2010)
Paper Presented At: 2010 Genitourinary Cancers Symposium
-
-
Choueiri, T.K.1
Xie, W.2
Kollmannsberger, C.K.3
-
24
-
-
70450159233
-
A population-based study examining the effect of tyrosine kinase inhibitors on survival in metastatic renal cell carcinoma in Alberta and the role of nephrectomy prior to treatment
-
M. Warren, P.M. Venner, and S. North A population-based study examining the effect of tyrosine kinase inhibitors on survival in metastatic renal cell carcinoma in Alberta and the role of nephrectomy prior to treatment Can Urol Assoc J 3 2009 281 289
-
(2009)
Can Urol Assoc J
, vol.3
, pp. 281-289
-
-
Warren, M.1
Venner, P.M.2
North, S.3
-
25
-
-
58149183664
-
Predictors of survival of advanced renal cell carcinoma: Long-term results from Southwest Oncology Group Trial S8949
-
P.N. Lara Jr., C.M. Tangen, S.J. Conlon, R.C. Flanigan, and E.D. Crawford Predictors of survival of advanced renal cell carcinoma: long-term results from Southwest Oncology Group Trial S8949 J Urol 181 2009 512 516 discussion 516-7
-
(2009)
J Urol
, vol.181
, pp. 512-516
-
-
Lara, Jr.P.N.1
Tangen, C.M.2
Conlon, S.J.3
Flanigan, R.C.4
Crawford, E.D.5
-
26
-
-
68949145218
-
Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma
-
R.J. Motzer, T.E. Hutson, and P. Tomczak Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma J Clin Oncol 27 2009 3584 3590
-
(2009)
J Clin Oncol
, vol.27
, pp. 3584-3590
-
-
Motzer, R.J.1
Hutson, T.E.2
Tomczak, P.3
-
27
-
-
58149181329
-
Response of the primary tumor to neoadjuvant sunitinib in patients with advanced renal cell carcinoma
-
A.A. Thomas, B.I. Rini, and B.R. Lane Response of the primary tumor to neoadjuvant sunitinib in patients with advanced renal cell carcinoma J Urol 181 2009 518 523 discussion 523
-
(2009)
J Urol
, vol.181
, pp. 518-523
-
-
Thomas, A.A.1
Rini, B.I.2
Lane, B.R.3
-
28
-
-
65049087191
-
Can tyrosine kinase inhibitors be discontinued in patients with metastatic renal cell carcinoma and a complete response to treatment? A multicentre, retrospective analysis
-
M. Johannsen, A. Flörcken, and A. Bex Can tyrosine kinase inhibitors be discontinued in patients with metastatic renal cell carcinoma and a complete response to treatment? A multicentre, retrospective analysis Eur Urol 55 2009 1430 1439
-
(2009)
Eur Urol
, vol.55
, pp. 1430-1439
-
-
Johannsen, M.1
Flörcken, A.2
Bex, A.3
-
29
-
-
33846698219
-
Patients with metastatic renal cell carcinoma with long-term disease-free survival after treatment with sunitinib and resection of residual metastases
-
B.I. Rini, V. Shaw, J.E. Rosenberg, S.T. Kim, and I. Chen Patients with metastatic renal cell carcinoma with long-term disease-free survival after treatment with sunitinib and resection of residual metastases Clin Genitourin Cancer 5 2006 232 234
-
(2006)
Clin Genitourin Cancer
, vol.5
, pp. 232-234
-
-
Rini, B.I.1
Shaw, V.2
Rosenberg, J.E.3
Kim, S.T.4
Chen, I.5
-
31
-
-
52949083899
-
Preoperative tyrosine kinase inhibition as an adjunct to debulking nephrectomy
-
C. Amin, E. Wallen, R.S. Pruthi, B.F. Calvo, P.A. Godley, and W.K. Rathmell Preoperative tyrosine kinase inhibition as an adjunct to debulking nephrectomy Urology 72 2008 864 868
-
(2008)
Urology
, vol.72
, pp. 864-868
-
-
Amin, C.1
Wallen, E.2
Pruthi, R.S.3
Calvo, B.F.4
Godley, P.A.5
Rathmell, W.K.6
-
32
-
-
46249087574
-
Neoadjuvant therapy with sorafenib in advanced renal cell carcinoma with vena cava extension submitted to radical nephrectomy
-
F. Di Silverio, A. Sciarra, and U. Parente Neoadjuvant therapy with sorafenib in advanced renal cell carcinoma with vena cava extension submitted to radical nephrectomy Urol Int 80 2008 451 453
-
(2008)
Urol Int
, vol.80
, pp. 451-453
-
-
Di Silverio, F.1
Sciarra, A.2
Parente, U.3
-
33
-
-
50049092572
-
Neoadjuvant targeted therapy and advanced kidney cancer: Observations and implications for a new treatment paradigm
-
B. Shuch, S.B. Riggs, and J.C. LaRochelle Neoadjuvant targeted therapy and advanced kidney cancer: observations and implications for a new treatment paradigm BJU Int 102 2008 692 696
-
(2008)
BJU Int
, vol.102
, pp. 692-696
-
-
Shuch, B.1
Riggs, S.B.2
Larochelle, J.C.3
-
34
-
-
43849100292
-
Neoadjuvant therapy for renal cancer [in French]
-
F. Thibault, O. Rixe, and J.B. Meric Neoadjuvant therapy for renal cancer [in French] Prog Urol 18 2008 256 258
-
(2008)
Prog Urol
, vol.18
, pp. 256-258
-
-
Thibault, F.1
Rixe, O.2
Meric, J.B.3
-
35
-
-
44649192971
-
Surgical morbidity associated with administration of targeted molecular therapies before cytoreductive nephrectomy or resection of locally recurrent renal cell carcinoma
-
V. Margulis, S.F. Matin, and N. Tannir Surgical morbidity associated with administration of targeted molecular therapies before cytoreductive nephrectomy or resection of locally recurrent renal cell carcinoma J Urol 180 2008 94 98
-
(2008)
J Urol
, vol.180
, pp. 94-98
-
-
Margulis, V.1
Matin, S.F.2
Tannir, N.3
-
36
-
-
35548987275
-
Perioperative sunitinib dosing around extensive resections of imatinib-resistant metastatic gastrointestinal stromal tumors
-
C. Raut, J. Morgan, and M. Quigley Perioperative sunitinib dosing around extensive resections of imatinib-resistant metastatic gastrointestinal stromal tumors J Clin Oncol 25 2007 10044
-
(2007)
J Clin Oncol
, vol.25
, pp. 10044
-
-
Raut, C.1
Morgan, J.2
Quigley, M.3
-
37
-
-
42249091688
-
Sunitinib for treatment of advanced renal cell cancer: Primary tumor response
-
A.A. Van der Veldt, M.R. Meijerink, and A.J. van den Eertwegh Sunitinib for treatment of advanced renal cell cancer: primary tumor response Clin Cancer Res 14 2008 2431 2436
-
(2008)
Clin Cancer Res
, vol.14
, pp. 2431-2436
-
-
Van Der Veldt, A.A.1
Meijerink, M.R.2
Van Den Eertwegh, A.J.3
-
38
-
-
39749085432
-
Short preoperative treatment with erlotinib inhibits tumor cell proliferation in hormone receptor-positive breast cancers
-
M. Guix, M. Granja Nde, and I. Meszoely Short preoperative treatment with erlotinib inhibits tumor cell proliferation in hormone receptor-positive breast cancers J Clin Oncol 26 2008 897 906
-
(2008)
J Clin Oncol
, vol.26
, pp. 897-906
-
-
Guix, M.1
Granja Nde, M.2
Meszoely, I.3
-
39
-
-
33846867459
-
Multimodal approaches in the management of locally advanced and metastatic renal cell carcinoma: Combining surgery and systemic therapies to improve patient outcome
-
C.G. Wood Multimodal approaches in the management of locally advanced and metastatic renal cell carcinoma: combining surgery and systemic therapies to improve patient outcome Clin Cancer Res 13 2007 697s 702s
-
(2007)
Clin Cancer Res
, vol.13
-
-
Wood, C.G.1
-
40
-
-
70249115638
-
Phase II presurgical feasibility study of bevacizumab in untreated patients with metastatic renal cell carcinoma
-
E. Jonasch, C.G. Wood, and S.F. Matin Phase II presurgical feasibility study of bevacizumab in untreated patients with metastatic renal cell carcinoma J Clin Oncol 27 2009 4076 4081
-
(2009)
J Clin Oncol
, vol.27
, pp. 4076-4081
-
-
Jonasch, E.1
Wood, C.G.2
Matin, S.F.3
-
41
-
-
78049455213
-
-
Immediate surgery or surgery after sunitinib malate in treating patients with metastatic kidney cancer. US National Institutes of Health Web site AccessedMay5,2010
-
Immediate surgery or surgery after sunitinib malate in treating patients with metastatic kidney cancer. US National Institutes of Health Web site. http://clinicaltrials.gov/ct2/show/NCT01099423. Accessed May 5, 2010.
-
-
-
-
42
-
-
33749451335
-
Adjuvant therapy for renal cell carcinoma
-
K.M. Jacobsohn, and C.G. Wood Adjuvant therapy for renal cell carcinoma Semin Oncol 33 2006 576 582
-
(2006)
Semin Oncol
, vol.33
, pp. 576-582
-
-
Jacobsohn, K.M.1
Wood, C.G.2
-
43
-
-
10744230275
-
Adjuvant autologous renal tumour cell vaccine and risk of tumour progression in patients with renal-cell carcinoma after radical nephrectomy: Phase III, randomised controlled trial
-
D. Jocham, A. Richter, and L. Hoffmann Adjuvant autologous renal tumour cell vaccine and risk of tumour progression in patients with renal-cell carcinoma after radical nephrectomy: phase III, randomised controlled trial Lancet 363 2004 594 599
-
(2004)
Lancet
, vol.363
, pp. 594-599
-
-
Jocham, D.1
Richter, A.2
Hoffmann, L.3
-
44
-
-
46749085802
-
An adjuvant autologous therapeutic vaccine (HSPPC-96; Vitespen) versus observation alone for patients at high risk of recurrence after nephrectomy for renal cell carcinoma: A multicentre, open-label, randomised phase III trial
-
C. Wood, P. Srivastava, and R. Bukowski An adjuvant autologous therapeutic vaccine (HSPPC-96; vitespen) versus observation alone for patients at high risk of recurrence after nephrectomy for renal cell carcinoma: a multicentre, open-label, randomised phase III trial Lancet 372 2008 145 154
-
(2008)
Lancet
, vol.372
, pp. 145-154
-
-
Wood, C.1
Srivastava, P.2
Bukowski, R.3
-
45
-
-
58149115366
-
Adjuvant therapy for renal cell carcinoma
-
N.B. Haas, and R. Uzzo Adjuvant therapy for renal cell carcinoma Curr Oncol Rep 10 2008 245 252
-
(2008)
Curr Oncol Rep
, vol.10
, pp. 245-252
-
-
Haas, N.B.1
Uzzo, R.2
-
46
-
-
65649108112
-
Patterns of disease progression in metastatic renal cell carcinoma patients treated with antivascular agents and interferon: Impact of therapy on recurrence patterns and outcome measures
-
E.R. Plimack, N. Tannir, E. Lin, B.N. Bekele, and E. Jonasch Patterns of disease progression in metastatic renal cell carcinoma patients treated with antivascular agents and interferon: impact of therapy on recurrence patterns and outcome measures Cancer 115 2009 1859 1866
-
(2009)
Cancer
, vol.115
, pp. 1859-1866
-
-
Plimack, E.R.1
Tannir, N.2
Lin, E.3
Bekele, B.N.4
Jonasch, E.5
-
47
-
-
60649087564
-
Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis
-
J.M. Ebos, C.R. Lee, W. Cruz-Munoz, G.A. Bjarnason, J.G. Christensen, and R.S. Kerbel Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis Cancer Cell 15 2009 232 239
-
(2009)
Cancer Cell
, vol.15
, pp. 232-239
-
-
Ebos, J.M.1
Lee, C.R.2
Cruz-Munoz, W.3
Bjarnason, G.A.4
Christensen, J.G.5
Kerbel, R.S.6
-
48
-
-
60649106195
-
Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis
-
M. Paez-Ribes, E. Allen, and J. Hudock Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis Cancer Cell 15 2009 220 231
-
(2009)
Cancer Cell
, vol.15
, pp. 220-231
-
-
Paez-Ribes, M.1
Allen, E.2
Hudock, J.3
-
49
-
-
69349105667
-
Adjuvant and neoadjuvant small-molecule targeted therapy in high-risk renal cell carcinoma
-
A. Kapoor, A. Gharajeh, A. Sheikh, and J. Pinthus Adjuvant and neoadjuvant small-molecule targeted therapy in high-risk renal cell carcinoma Curr Oncol 16 2009 S60 S66
-
(2009)
Curr Oncol
, vol.16
-
-
Kapoor, A.1
Gharajeh, A.2
Sheikh, A.3
Pinthus, J.4
-
50
-
-
34248369806
-
The evolving role of surgery for advanced renal cell carcinoma in the era of molecular targeted therapy
-
B.I. Rini, and S.C. Campbell The evolving role of surgery for advanced renal cell carcinoma in the era of molecular targeted therapy J Urol 177 2007 1978 1984
-
(2007)
J Urol
, vol.177
, pp. 1978-1984
-
-
Rini, B.I.1
Campbell, S.C.2
-
51
-
-
70749100131
-
Laparoscopic radical nephrectomy after shrinkage of a caval tumor thrombus with sunitinib
-
L.C. Harshman, S. Srinivas, A. Kamaya, and B.I. Chung Laparoscopic radical nephrectomy after shrinkage of a caval tumor thrombus with sunitinib Nat Rev Urol 6 2009 338 343
-
(2009)
Nat Rev Urol
, vol.6
, pp. 338-343
-
-
Harshman, L.C.1
Srinivas, S.2
Kamaya, A.3
Chung, B.I.4
-
52
-
-
39449121694
-
Neoadjuvant sutent induction therapy may effectively down-stage renal cell carcinoma atrial thrombi
-
P.I. Karakiewicz, N. Suardi, and C. Jeldres Neoadjuvant sutent induction therapy may effectively down-stage renal cell carcinoma atrial thrombi Eur Urol 53 2008 845 848
-
(2008)
Eur Urol
, vol.53
, pp. 845-848
-
-
Karakiewicz, P.I.1
Suardi, N.2
Jeldres, C.3
-
53
-
-
56249123229
-
Treatment with sunitinib enabled complete resection of massive lymphadenopathy not previously amenable to excision in a patient with renal cell carcinoma
-
J.-J. Patard, R. Thuret, A. Raffi, B. Laguerre, K. Bensalah, and S. Culine Treatment with sunitinib enabled complete resection of massive lymphadenopathy not previously amenable to excision in a patient with renal cell carcinoma Eur Urol 55 2009 237 239 quiz 239
-
(2009)
Eur Urol
, vol.55
, pp. 237-239
-
-
Patard, J.-J.1
Thuret, R.2
Raffi, A.3
Laguerre, B.4
Bensalah, K.5
Culine, S.6
-
54
-
-
66249097161
-
Complete histologic remission after sunitinib neoadjuvant therapy in T3b renal cell carcinoma
-
G. Robert, G. Gabbay, and R. Bram Complete histologic remission after sunitinib neoadjuvant therapy in T3b renal cell carcinoma Eur Urol 55 2009 1477 1480
-
(2009)
Eur Urol
, vol.55
, pp. 1477-1480
-
-
Robert, G.1
Gabbay, G.2
Bram, R.3
-
55
-
-
68549091054
-
Neoadjuvant sunitinib for surgically complex advanced renal cell cancer of doubtful resectability: Initial experience with downsizing to reconsider cytoreductive surgery
-
A. Bex, A.A. van der Veldt, and C. Blank Neoadjuvant sunitinib for surgically complex advanced renal cell cancer of doubtful resectability: initial experience with downsizing to reconsider cytoreductive surgery World J Urol 27 2009 533 539
-
(2009)
World J Urol
, vol.27
, pp. 533-539
-
-
Bex, A.1
Van Der Veldt, A.A.2
Blank, C.3
-
56
-
-
84856223670
-
Does targeted therapy result in reliable and meaningful primary tumor downstaging in patients with metastatic renal cell carcinoma?
-
March 5-7 San Francisco, CA, USA
-
Abel EJ, Tannir NM, Culp SH, Matin SF, Jonasch E, Wood CG. Does targeted therapy result in reliable and meaningful primary tumor downstaging in patients with metastatic renal cell carcinoma? Paper presented at: Proceedings of the 2010 Genitourinary Cancers Symposium; March 5-7, 2010; San Francisco, CA, USA.
-
(2010)
Paper Presented At: Proceedings of the 2010 Genitourinary Cancers Symposium
-
-
Abel, E.J.1
Tannir, N.M.2
Culp, S.H.3
Matin, S.F.4
Jonasch, E.5
Wood, C.G.6
-
57
-
-
78049485504
-
The safety and efficacy of sunitinib prior to planned nephrectomy in metastatic clear cell renal cancer
-
March 5-7 San Francisco, CA, USA
-
Powles T, Kayani I, Blank C, et al. The safety and efficacy of sunitinib prior to planned nephrectomy in metastatic clear cell renal cancer. Poster presented at: Proceedings of the 2010 Genitourinary Cancers Symposium; March 5-7, 2010; San Francisco, CA, USA.
-
(2010)
Poster Presented At: Proceedings of the 2010 Genitourinary Cancers Symposium
-
-
Powles, T.1
Kayani, I.2
Blank, C.3
-
58
-
-
76249126867
-
Sunitinib acts primarily on tumor endothelium rather than tumor cells to inhibit the growth of renal cell carcinoma
-
Huang D, Ding Y, Li Y, et al. Sunitinib acts primarily on tumor endothelium rather than tumor cells to inhibit the growth of renal cell carcinoma. Cancer Res 70:1053-62.
-
Cancer Res
, vol.70
, pp. 1053-62
-
-
Huang, D.1
Ding, Y.2
Li, Y.3
-
59
-
-
78049458544
-
-
Sunitinib in treating patients with kidney cancer that cannot be removed by surgery. US National Institutes of Health Web site AccessedMay5,2010
-
Sunitinib in treating patients with kidney cancer that cannot be removed by surgery. US National Institutes of Health Web site. http://clinicaltrials. gov/ct2/show/NCT00459979?term=kidney+cancer+surgery&rank=13. Accessed May 5, 2010.
-
-
-
-
60
-
-
68149125532
-
Surgical resection of renal cell carcinoma after targeted therapy
-
A.A. Thomas, B.I. Rini, and A.J. Stephenson Surgical resection of renal cell carcinoma after targeted therapy J Urol 182 2009 881 886
-
(2009)
J Urol
, vol.182
, pp. 881-886
-
-
Thomas, A.A.1
Rini, B.I.2
Stephenson, A.J.3
-
61
-
-
33748807076
-
Molecular mechanisms of VEGF-A action during tissue repair
-
S.A. Eming, and T. Krieg Molecular mechanisms of VEGF-A action during tissue repair J Investig Dermatol Symp Proc 11 2006 79 86
-
(2006)
J Investig Dermatol Symp Proc
, vol.11
, pp. 79-86
-
-
Eming, S.A.1
Krieg, T.2
-
62
-
-
33845490014
-
Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer
-
A. Sandler, R. Gray, and M.C. Perry Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer N Engl J Med 355 2006 2542 2550
-
(2006)
N Engl J Med
, vol.355
, pp. 2542-2550
-
-
Sandler, A.1
Gray, R.2
Perry, M.C.3
-
63
-
-
34548141828
-
Arterial thromboembolic events in patients with metastatic carcinoma treated with chemotherapy and bevacizumab
-
F.A. Scappaticci, J.R. Skillings, and S.N. Holden Arterial thromboembolic events in patients with metastatic carcinoma treated with chemotherapy and bevacizumab J Natl Cancer Inst 99 2007 1232 1239
-
(2007)
J Natl Cancer Inst
, vol.99
, pp. 1232-1239
-
-
Scappaticci, F.A.1
Skillings, J.R.2
Holden, S.N.3
-
64
-
-
2542561964
-
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer
-
H. Hurwitz, L. Fehrenbacher, and W. Novotny Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer N Engl J Med 350 2004 2335 2342
-
(2004)
N Engl J Med
, vol.350
, pp. 2335-2342
-
-
Hurwitz, H.1
Fehrenbacher, L.2
Novotny, W.3
-
65
-
-
21244481589
-
High-dose bevacizumab improves survival when combined with FOLFOX4 in previously treated advanced colorectal cancer: Results from the Eastern Cooperative Oncology Group (ECOG) study E3200
-
B.J. Giantonio, P.J. Catalano, and N.J. Meropol High-dose bevacizumab improves survival when combined with FOLFOX4 in previously treated advanced colorectal cancer: Results from the Eastern Cooperative Oncology Group (ECOG) study E3200 J Clin Oncol 23 2005 2
-
(2005)
J Clin Oncol
, vol.23
, pp. 2
-
-
Giantonio, B.J.1
Catalano, P.J.2
Meropol, N.J.3
-
66
-
-
77951886671
-
Neoadjuvant clinical trial with sorafenib for patients with stage II or higher renal cell carcinoma
-
C.L. Cowey, C. Amin, and R.S. Pruthi Neoadjuvant clinical trial with sorafenib for patients with stage II or higher renal cell carcinoma J Clin Oncol 28 2010 1502 1507
-
(2010)
J Clin Oncol
, vol.28
, pp. 1502-1507
-
-
Cowey, C.L.1
Amin, C.2
Pruthi, R.S.3
-
67
-
-
3242713145
-
Classification of surgical complications: A new proposal with evaluation in a cohort of 6336 patients and results of a survey
-
D. Dindo, N. Demartines, and P.A. Clavien Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey Ann Surg 240 2004 205 213
-
(2004)
Ann Surg
, vol.240
, pp. 205-213
-
-
Dindo, D.1
Demartines, N.2
Clavien, P.A.3
-
68
-
-
64549104195
-
Tolerability of first-line therapy for metastatic renal cell carcinoma
-
C. Porta, and C. Szczylik Tolerability of first-line therapy for metastatic renal cell carcinoma Cancer Treat Rev 35 2009 297 307
-
(2009)
Cancer Treat Rev
, vol.35
, pp. 297-307
-
-
Porta, C.1
Szczylik, C.2
-
69
-
-
39049095199
-
Pazopanib, a potent orally administered small-molecule multitargeted tyrosine kinase inhibitor for renal cell carcinoma
-
G. Sonpavde, T.E. Hutson, and C.N. Sternberg Pazopanib, a potent orally administered small-molecule multitargeted tyrosine kinase inhibitor for renal cell carcinoma Expert Opin Investig Drugs 17 2008 253 261
-
(2008)
Expert Opin Investig Drugs
, vol.17
, pp. 253-261
-
-
Sonpavde, G.1
Hutson, T.E.2
Sternberg, C.N.3
-
70
-
-
70449523183
-
Myelosuppression and kinase selectivity of multikinase angiogenesis inhibitors
-
R. Kumar, M.C. Crouthamel, and D.H. Rominger Myelosuppression and kinase selectivity of multikinase angiogenesis inhibitors Br J Cancer 101 2009 1717 1723
-
(2009)
Br J Cancer
, vol.101
, pp. 1717-1723
-
-
Kumar, R.1
Crouthamel, M.C.2
Rominger, D.H.3
-
71
-
-
35448934762
-
Axitinib treatment in patients with cytokine-refractory metastatic renal-cell cancer: A phase II study
-
O. Rixe, R.M. Bukowski, and M.D. Michaelson Axitinib treatment in patients with cytokine-refractory metastatic renal-cell cancer: a phase II study Lancet Oncol 8 2007 975 984
-
(2007)
Lancet Oncol
, vol.8
, pp. 975-984
-
-
Rixe, O.1
Bukowski, R.M.2
Michaelson, M.D.3
-
72
-
-
36549025941
-
Phase II study of the angiogenesis inhibitor AZD2171 in first line, progressive, unresectable, advanced metastatic renal cell carcinoma (RCC): A trial of the PMH Phase II Consortium
-
S.S. Sridhar, S.J. Hotte, and M.J. Mackenzie Phase II study of the angiogenesis inhibitor AZD2171 in first line, progressive, unresectable, advanced metastatic renal cell carcinoma (RCC): A trial of the PMH Phase II Consortium J Clin Oncol 25 2007 5093
-
(2007)
J Clin Oncol
, vol.25
, pp. 5093
-
-
Sridhar, S.S.1
Hotte, S.J.2
MacKenzie, M.J.3
-
73
-
-
63449138139
-
Activity of cediranib (AZD2171) in patients (pts) with previously untreated metastatic renal cell cancer (RCC). A phase II trial of the PMH Consortium
-
S.S. Sridhar, M.J. Mackenzie, and S.J. Hotte Activity of cediranib (AZD2171) in patients (pts) with previously untreated metastatic renal cell cancer (RCC). A phase II trial of the PMH Consortium J Clin Oncol 26 2008 5047
-
(2008)
J Clin Oncol
, vol.26
, pp. 5047
-
-
Sridhar, S.S.1
MacKenzie, M.J.2
Hotte, S.J.3
-
74
-
-
78049475481
-
Activity of tivozanib (AV-951) in patients with renal cell carcinoma (RCC): Subgroup analysis from a phase II randomized discontinuation trial (RDT)
-
P. Bhargava, B. Esteves, and M. Al-Adhami Activity of tivozanib (AV-951) in patients with renal cell carcinoma (RCC): Subgroup analysis from a phase II randomized discontinuation trial (RDT) J Clin Oncol 28 2010 4599
-
(2010)
J Clin Oncol
, vol.28
, pp. 4599
-
-
Bhargava, P.1
Esteves, B.2
Al-Adhami, M.3
-
75
-
-
78049483284
-
-
Sunitinib or sorafenib in treating patients with kidney cancer that was removed by surgery. US National Institutes of Health Web site AccessedMay5,2010
-
Sunitinib or sorafenib in treating patients with kidney cancer that was removed by surgery. US National Institutes of Health Web site. http://clinicaltrials.gov/ct2/show/NCT00326898. Accessed May 5, 2010.
-
-
-
-
76
-
-
78049487131
-
-
A clinical trial comparing efficacy and safety of sunitinib versus placebo for the treatment of patients at high risk of recurrent renal cell cancer (S-TRAC). US National Institutes of Health Web site
-
A clinical trial comparing efficacy and safety of sunitinib versus placebo for the treatment of patients at high risk of recurrent renal cell cancer (S-TRAC). US National Institutes of Health Web site. http:// clinicaltrials.gov/ct2/show/NCT00375674. Accessed July 28, 2010.
-
-
-
-
77
-
-
78049482928
-
-
Sorafenib in treating patients at risk of relapse after undergoing surgery to remove kidney cancer. US National Institutes of Health Web site AccessedJuly28,2010
-
Sorafenib in treating patients at risk of relapse after undergoing surgery to remove kidney cancer. US National Institutes of Health Web site. http://clinicaltrials.gov/ct2/show/NCT00492258. Accessed July 28, 2010.
-
-
-
-
78
-
-
78049484172
-
-
Everolimus in treating patients with kidney cancer who have undergone surgery. US National Institutes of Health Web site
-
Everolimus in treating patients with kidney cancer who have undergone surgery. US National Institutes of Health Web site. http://clinicaltrials.gov/ ct2/show/NCT01120249?term=EVEREST&rank=7. Accessed May 5, 2010.
-
-
-
|